Search results for "LIPIDS"

showing 10 items of 2228 documents

Low-density lipoproteins generated during an oral fat load in mild hypertriglyceridemic and healthy subjects are smaller, denser, and have an increas…

2005

Triglyceride-rich lipoproteins generated during the postprandial phase are atherogenic. Large very low-density lipoproteins (LDLs) or chylomicrons (CMs) are not as atherogenic as their remnants (Rem). Small and dense LDLs are associated with cardiovascular disease. Low-density lipoprotein size is partly under genetic control and is considered as a relatively stable LDL feature. In this article, we present data on retinyl palmitate kinetics correlated with the modification of LDL features in terms of size, density, and in vitro receptor binding affinity after an oral fat load. Six nondiabetic, hypertriglyceridemic (HTG) patients and 6 healthy controls were examined. Low-density lipoprotein s…

AdultMalemedicine.medical_specialtyRetinyl EstersSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismBinding CompetitiveModels Biologicalchemistry.chemical_compoundEndocrinologyInternal medicineRetinyl palmitateCell Line TumorChylomicronsmedicineHumansReceptorVitamin AHypertriglyceridemiaLow-density lipoproteins hypertriglyceridemia Fasting and postprandial LDLsTriglycerideCatabolismChemistryFastingFibroblastsPostprandial PeriodDietary FatsLipidsLipoproteins LDLKineticsEndocrinologyPostprandialReceptors LDLlipids (amino acids peptides and proteins)Density gradient ultracentrifugationElectrophoresis Polyacrylamide GelFemaleDiterpenesUltracentrifugationLipoproteinChylomicronMetabolism: clinical and experimental
researchProduct

Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholeste…

2017

Homozygous familial hypercholesterolemia is a genetic disorder characterized by low-density lipoprotein (LDL)-receptor dysfunction, markedly elevated levels of LDL-cholesterol (LDL-C) and premature atherosclerosis. Patients are often poorly responsive to conventional lipid-lowering therapies that upregulate LDL-receptor expression.1 Lomitapide inhibits microsomal triglyceride transfer protein, which lipidates nascent apolipoprotein (apo)B-containing lipoproteins. In a pivotal 78-week open-label trial, lomitapide, titrated to the maximal tolerable dose, decreased LDL-C by 50% at the end of the efficacy phase (week 26) in patients with homozygous familial hypercholesterolemia.2 The principal …

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BSocio-culturaleFamilial hypercholesterolemia030204 cardiovascular system & hematologyGastroenterologyMicrosomal triglyceride transfer proteinLDLTimeSudden cardiac deathHyperlipoproteinemia Type II03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhysiology (medical)Internal medicinemedicineHumans030212 general & internal medicineAdverse effectlomitapidebiologybusiness.industryCholesterolAnticholesteremic AgentsCholesterol LDLlomitapide; Adult; Anticholesteremic Agents; Benzimidazoles; Carrier Proteins; Cholesterol LDL; Female; Humans; Hyperlipoproteinemia Type II; Male; Timemedicine.diseaseLomitapideCholesterolEndocrinologychemistrybiology.proteinBenzimidazolesFemalelipids (amino acids peptides and proteins)lomitapide; Cardiology and Cardiovascular Medicine; Physiology (medical)Carrier ProteinsCardiology and Cardiovascular MedicinebusinessLipoproteinCirculation
researchProduct

Ezetimibe alone or in combination with simvastatin increases small, dense low-density lipoproteins in healthy men: a randomized trial

2010

Aims The predominance of small dense low-density lipoproteins (sdLDLs) has been associated with increased cardiovascular risk. The effect of ezetimibe on LDL subfraction distribution has not been fully elucidated. This study assessed by gradient gel electrophoresis the effects of ezetimibe alone, simvastatin alone, and their combination on sdLDL subfraction distribution. Methods and results A single-centre, randomized, parallel three-group open-label study was performed in 72 healthy men with a baseline LDL-cholesterol (LDL-C) concentration of 111 ± 30 mg/dL (2.9 ± 0.8 mmol/L). They were treated with ezetimibe (10 mg/day, n = 24), simvastatin (40 mg/day, n = 24), or their combination ( n = …

AdultMalemedicine.medical_specialtySimvastatinRandomizationCombination therapyAdolescent10265 Clinic for Endocrinology and Diabetology610 Medicine & health2705 Cardiology and Cardiovascular Medicinelaw.inventionYoung AdultRandomized controlled trialEzetimibelawInternal medicinemedicineDistribution (pharmacology)HumansDrug Interactionsbiologybusiness.industryAnticholesteremic AgentsLipoprotein(a)Middle AgedEzetimibeLipoproteins LDLEndocrinologySimvastatinMultivariate Analysisbiology.proteinAzetidineslipids (amino acids peptides and proteins)Drug Therapy CombinationElectrophoresis Polyacrylamide GelatherosclerosisCardiology and Cardiovascular MedicinebusinessBody mass indexmedicine.drug
researchProduct

Pravastatin reverses the membrane cholesterol reorganization induced by myocardial infarction within lipid rafts in CD14(+)/CD16(-) circulating monoc…

2012

International audience; Large numbers of monocytes are recruited in the infarcted myocardium. Their cell membranes contain cholesterol-rich microdomains called lipids rafts, which participate in numerous signaling cascades. In addition to its cholesterol-lowering effect, pravastatin has several pleiotropic effects and is widely used as secondary prevention treatment after myocardial infarction (MI). The aim of this study was to investigate the effects of pravastatin on the organization of cholesterol within monocyte membrane rafts from patients who had suffered myocardial infarction. Monocytes from healthy donors and acute MI patients were cultured with or without 4μM pravastatin. Lipid raf…

AdultMalemedicine.medical_specialtyStatinmedicine.drug_classCD14[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionCaveolin 1Lipopolysaccharide Receptors030204 cardiovascular system & hematologyCD16GPI-Linked ProteinsMonocytes03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCaveolaeInternal medicinemedicineHumansMolecular BiologyLipid raftCells Cultured030304 developmental biologyPravastatin0303 health sciencesCholesterolMonocyteAnticholesteremic AgentsReceptors IgGstatinCell BiologyMiddle Aged3. Good healthlipid raftEndocrinologymedicine.anatomical_structureCholesterolmyocardial infarctionchemistryGene Expression RegulationImmunologycaveolaemonocyteFemalelipids (amino acids peptides and proteins)[SDV.AEN]Life Sciences [q-bio]/Food and NutritionPravastatinmedicine.drug
researchProduct

Effects of strength and endurance training on metabolic risk factors in healthy 40–65-year-old men

2009

This study compared 21 weeks of combined high-intensity strength and endurance training with endurance or strength training only on metabolic risk factors in 40-65-year-old men. The healthy men (n=63) were randomized into endurance (E), strength (S), combined strength and endurance training (SE) and control (C) groups. S and E trained two times a week and SE 2+2 times a week. Systolic (SBP) and diastolic blood pressure decreased significantly both in E (-6+/-8 and -4+/-6 mmHg) and in S (-9+/-8 and -5+/-7 mmHg), but not in SE or C (P=0.003 for the difference in the changes of SBP between the groups). The changes in serum glucose and insulin during an oral glucose tolerance test did not diffe…

AdultMalemedicine.medical_specialtyStrength trainingLipoproteinsPhysical fitnessBlood lipidsBlood PressurePhysical Therapy Sports Therapy and RehabilitationOxygen ConsumptionRisk FactorsEndurance trainingInternal medicineHumansInsulinMedicineOrthopedics and Sports MedicineFinlandAgedAnthropometrybusiness.industryVO2 maxResistance TrainingCardiorespiratory fitnessMiddle Agedmedicine.diseaseGlucoseBlood pressureEndocrinologyExercise TestPhysical EnduranceMetabolic syndromeEnergy MetabolismbusinessScandinavian Journal of Medicine & Science in Sports
researchProduct

Imaging findings of hepatic focal nodular hyperplasia in men and women: are they really different?

2014

Purpose This study was undertaken to compare the imaging findings of focal nodular hyperplasia (FNH) in men and women, as seen on multidetector computed tomography (MDCT), magnetic resonance imaging (MRI) and contrast-enhanced ultrasound (CEUS). Materials and methods Two radiologists reviewed 195 imaging studies (17 MDCT, 81 MRI and 97 CEUS examinations) pertaining to 111 FNHs (mean size 3 cm) in 91 patients (mean age 39 years). For each lesion, the readers assessed size, location, echogenicity, attenuation, or signal intensity in comparison with adjacent liver parenchyma on both unenhanced and postcontrast images. Results Eighty-nine FNHs (mean size 3.1 cm) were observed in 73 women (mean …

AdultMalemedicine.medical_specialtySulfur HexafluorideContrast MediaSettore MED/01 - Statistica MedicaMeglumineSex FactorsSex factorsMultidetector computed tomographyMultidetector Computed TomographyOrganometallic CompoundsMedicineHumansRadiology Nuclear Medicine and imagingcardiovascular diseasesPhospholipidsNeuroradiologyAgedmedicine.diagnostic_testbusiness.industryUltrasoundFocal nodular hyperplasiaMagnetic resonance imagingInterventional radiologyGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance ImagingFocal nodular hyperplasia liver Computed tomographyMagnetic resonance imagingContrast-enhanced ultrasoundIopamidolFocal Nodular Hyperplasiacardiovascular systemFemaleRadiologybusinessSettore MED/36 - Diagnostica Per Immagini E RadioterapiaContrast-enhanced ultrasound
researchProduct

Ultrasonic evaluation with second harmonic imaging and SonoVue in the assessment of cerebral perfusion in diabetic patients: a case-control study

2004

The purpose was to compare human brain tissue perfusion in diabetic patients and healthy subjects with second harmonic imaging ultrasound and SonoVue to test the hypothesis that brain tissue perfusion differences are present in these two groups of patients. In a prospective case-control study, second harmonic examinations performed in 20 patients with type II diabetes mellitus and in 20 matched control patients were compared. After administration of 2.5 ml of SonoVue, 60 time-triggered images were recorded. Time-intensity curves, including peak intensity and positive gradient normalized to the middle cerebral artery, were calculated to quantify ultrasound intensity in a region of interest. …

AdultMalemedicine.medical_specialtySulfur Hexafluoridemedicine.arteryInternal medicineUltrasoundHumansMedicineRadiology Nuclear Medicine and imagingProspective StudiesCerebral perfusion pressurePhospholipidsAgedUltrasonographyNeuroradiologyHarmonic studybusiness.industryContrast mediaUltrasoundCase-control studyBrainGeneral MedicineBlood flowBlood flowMiddle AgedSurgeryIntensity (physics)PerfusionDiabetes Mellitus Type 2Case-Control StudiesCerebrovascular CirculationMiddle cerebral arteryCardiologyFemaleRadiologybusinessPerfusion
researchProduct

Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-t…

2007

Objective: Patients with growth hormone deficiency (GHD) have increased cardiovascular risk and may show elevated triglyceride and reduced high density lipoprotein (HDL) cholesterol concentrations, two lipid abnormalities usually accompanied by increased small dense LDL in the ‘atherogenic lipoprotein phenotype’ (ALP). In the present study, we directly investigated (1) whether hypopituitary patients with GHD have increased small dense LDL; (2) whether growth hormone replacement therapy (GHRT) beneficially impact on such particles; (3) the prevalence of ALP in GHD and GHRT patients. Design and methods: In 14 hypopituitary patients with GHD (44 ± 13 years, body mass index (BMI) 27 ± 3) before…

AdultMalemedicine.medical_specialtyTime FactorsArteriosclerosisHormone Replacement TherapyEndocrinology Diabetes and MetabolismBiologyHypopituitarismGrowth hormone deficiencychemistry.chemical_compoundEndocrinologyInternal medicinemedicineHumansIn patientInsulin-Like Growth Factor ITriglyceridesTriglycerideHuman Growth HormoneCholesterolVascular diseaseCholesterol HDLGeneral MedicineMiddle AgedAtherogenic lipoprotein phenotypemedicine.diseaseLipoproteins LDLCholesterolTreatment OutcomeEndocrinologyAtheromachemistryLow-density lipoproteinElectrophoresis Polyacrylamide GelFemalelipids (amino acids peptides and proteins)European Journal of Endocrinology
researchProduct

Centrifugal (inside-out) enhancement of liver hemangiomas: a possible atypical appearance on contrast-enhanced US.

2007

Abstract Objective To report the prevalence and to describe the atypical centrifugal (inside-out) appearance of contrast-enhancement of liver hemangiomas on contrast-enhanced sonography. Materials and methods Baseline and SonoVue ® -enhanced ultrasonography of 92 patients with 158 liver hemangiomas – considered atypical at grey-scale examination and confirmed by computed tomography, magnetic resonance imaging and ultrasound follow-up – were reviewed in consensus by two experienced radiologists, who evaluated baseline echogenicity and the dynamic enhancement pattern of each lesion looking for the presence of central enhancing foci in the arterial phase followed by a centrifugal (inside-out) …

AdultMalemedicine.medical_specialtyTime FactorsSecond-harmonic imaging microscopySulfur HexafluorideContrast MediaAngiomaHepatic ArterymedicineImage Processing Computer-AssistedHumansRadiology Nuclear Medicine and imagingUltrasonography Doppler ColorPhospholipidsAgedMicrobubblesmedicine.diagnostic_testbusiness.industryVascular diseasePortal VeinUltrasoundLiver NeoplasmsEchogenicityMagnetic resonance imagingUltrasonography DopplerGeneral MedicineMiddle Agedmedicine.diseaseImage EnhancementMagnetic Resonance ImagingUltrasonography Doppler PulsedLiver HemangiomaFemaleRadiologyTomographybusinessHemangiomaTomography X-Ray ComputedFollow-Up StudiesEuropean journal of radiology
researchProduct

Changes in plasma lecithin: cholesterol acyltransferase activity, HDL2, HDL3 amounts and compositions in patients with chronic renal failure after di…

2002

The aim of this study was to investigate the effect of hemodialysis duration on HDL(2) and HDL(3) compositions and lecithin:cholesterol acyltransferase (LCAT) activity in 58 patients on acetate hemodialysis using cuprophane membrane, after different periods of dialysis. Patients were divided into three groups-GI1 year, GII 1-5 years, GIII 5-13 years of dialysis and were compared with 22 controls. Increase by 34% of triacylglycerols (TG) was noted in GI and by 36% in GII versus GI. Hypertriglyceridemia was correlated with hemodialysis duration (HD) (r=0.75, P0.05). The LCAT activity decrease by 25% was noted in GII versus GI (P0.05) and by 45% in GIII versus GI (P0.01), this activity was neg…

AdultMalemedicine.medical_specialtyTime Factorsfood.ingredientmedicine.medical_treatmentSterol O-acyltransferaseLecithinPhosphatidylcholine-Sterol O-AcyltransferasefoodRenal DialysisInternal medicinemedicineHumansTriglyceridesDialysisbusiness.industryCuprophaneLipoproteins HDL3Middle Agedmedicine.diseaseLipoproteins HDL2EndocrinologyKidney Failure ChronicChronic renal failureFemalelipids (amino acids peptides and proteins)Phosphatidylcholine—sterol O-acyltransferaseHemodialysisLipoproteins HDLCardiology and Cardiovascular MedicinebusinessKidney diseaseAtherosclerosis
researchProduct